Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging protein kinase inhibitors for non-small cell lung cancer

20 Dec 2013

Abstract excerpt

INTRODUCTION: In the current paradigm of precision medicine in non-small cell lung cancer (NSCLC), the therapeutic strategy is determined by the molecular characteristics. The best examples of this approach are the kinase inhibitors that selectively target tumors bearing an epidermal growth factor receptor (EGFR) mutation or an anaplastic lymphoma kinase (ALK) rearrangement. Emerging protein kinase inhibitors may...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fibroblast Growth Factor Research
Share to Lung Cancer Treatments and Mutations
Share to Melanoma and MAPK Pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24354593
DOI: 10.1517/14728214.2014.873403

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging protein kinase inhibitors for non-small cell lung cancerPMID 24354593Read ↗

Management and future directions in non-small cell lung cancer with known activating mutations.Semantic proximity Read ↗

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.Semantic proximity Read ↗

Novel Emerging Molecular Targets in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Emerging targeted therapies in non-small cell lung cancer.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusionSemantic proximity Read ↗

Targeting emerging molecular alterations in the treatment of non-small cell lung cancer: current challenges and the way forward.Semantic proximity Read ↗

Targeted therapy for lung cancer: Beyond EGFR and ALK.Semantic proximity Read ↗

Molecular target therapeutics of EGF-TKI and downstream signaling pathways in non-small cell lung cancers.Semantic proximity Read ↗

Targeted therapies for treatment of non-small cell lung cancer--Recent advances and future perspectives.Semantic proximity Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.